GlassScriptPhysician profile
Keith L Callahan
NPI 1629063219
$4,342.86
in general payments reported to CMS, 2019-2025
31 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $638 · 2021: $1,043 · 2022: $513 · 2023: $413 · 2024: $521 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,365 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,365.35 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $804.64 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $614.25 | 2019-2024 | Jardiance, Spiriva Respimat, Stiolto Respimat |
| Pfizer INC. | $437.62 | 2020-2024 | |
| Astrazeneca Pharmaceuticals LP | $403.73 | 2019-2024 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $354.20 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $332.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $259.91 | 2019-2024 | Mounjaro, Zepbound |
| Abbvie INC. | $159.78 | 2021-2025 | Qulipta |
| Exact Sciences Corporation | $145.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $82.46 | 2022-2024 | |
| Amgen INC. | $67.23 | 2025 | Repatha |
| Mylan Specialty L.P. | $61.92 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $61.78 | 2019 | |
| Verona Pharma, INC. | $61.11 | 2025 | Ohtuvayre |
| Abbott Laboratories | $54.47 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $50.54 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $45.31 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $40.33 | 2020-2021 | |
| Lundbeck LLC | $40.23 | 2025 | Rexulti |
| Astellas Pharma US INC | $39.54 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.85 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $29.23 | 2021 | |
| Paratek Pharmaceuticals, INC. | $23.34 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $23.23 | 2019 | |
| Xeris Pharmaceuticals, INC. | $19.63 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.04 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $17.49 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.23 | 2023 | Rebyota |
| Eisai INC. | $15.96 | 2022 | |
| Esperion Therapeutics, INC. | $15.34 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Callahan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.